Mersana Therapeutics, Inc. Logo

Mersana Therapeutics, Inc.

Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.

MRSN | US

Overview

Corporate Details

ISIN(s):
US59045L1061
LEI:
Country:
United States of America
Address:
840 MEMORIAL DRIVE, 2139 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients with cancer. The company utilizes its proprietary and innovative ADC platforms, which employ both cytotoxic and immunostimulatory payloads. These platforms are designed to overcome the limitations of first-generation ADCs by allowing for the customization and optimization of therapies to improve efficacy and tolerability. Mersana is advancing a pipeline of ADCs that target multiple tumor types with high unmet medical needs, aiming to provide meaningful benefits to people fighting cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Mersana Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mersana Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mersana Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America
MRUS
MESOBLAST LTD Logo
Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.
United States of America
MESO
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America
MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America
MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea
140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea
432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America
MIST
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America
MDXG

Talk to a Data Expert

Have a question? We'll get back to you promptly.